Most cited article - PubMed ID 23114617
Antimycobacterial assessment of Salicylanilide benzoates including multidrug-resistant tuberculosis strains
The development of novel inhibitors of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) represents a viable approach to alleviate Alzheimer's disease. Thirty-six halogenated 2-hydroxy-N-phenylbenzamides (salicylanilides) with various substitution patterns and their esters with phosphorus-based acids were synthesized in yields of 72% to 92% and characterized. They were evaluated for in vitro inhibition of AChE from electric eel and BuChE from equine serum using modified Ellman's spectrophotometric method. The benzamides exhibited a moderate inhibition of AChE with IC50 values in a narrow concentration range from 33.1 to 85.8 µM. IC50 values for BuChE were higher (53.5-228.4 µM). The majority of derivatives inhibit AChE more efficiently than BuChE and are comparable or superior to rivastigmine-an established cholinesterases inhibitor used in the treatment of Alzheimer's disease. Phosphorus-based esters especially improved the activity against BuChE with 5-chloro-2-{[4-(trifluoromethyl)phenyl]carbamoyl}phenyl diethyl phosphite 5c superiority (IC50 = 2.4 µM). This derivative was also the most selective inhibitor of BuChE. It caused a mixed inhibition of both cholinesterases and acted as a pseudo-irreversible inhibitor. Several structure-activity relationships were identified, e.g., favouring esters and benzamides obtained from 5-halogenosalicylic acids and polyhalogenated anilines. Both 2-hydroxy-N-phenylbenzamides and esters share convenient physicochemical properties for blood-brain-barrier penetration and thus central nervous system delivery.
- Keywords
- acetylcholinesterase, benzamides, butyrylcholinesterase, enzyme inhibition, esters, in vitro inhibition, phosphorus derivatives, salicylanilides,
- MeSH
- Acetylcholinesterase metabolism MeSH
- Benzamides chemistry pharmacology MeSH
- Butyrylcholinesterase metabolism MeSH
- Cholinesterase Inhibitors chemistry pharmacology MeSH
- Electrophorus MeSH
- Esters chemistry pharmacology MeSH
- Phosphorus chemistry MeSH
- Inhibitory Concentration 50 MeSH
- Horses MeSH
- Molecular Structure MeSH
- Structure-Activity Relationship MeSH
- Animals MeSH
- Check Tag
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Acetylcholinesterase MeSH
- Benzamides MeSH
- Butyrylcholinesterase MeSH
- Cholinesterase Inhibitors MeSH
- Esters MeSH
- Phosphorus MeSH
The development of novel antimicrobial agents represents a timely research topic. Eighteen salicylanilide 4-(trifluoromethyl)benzoates were evaluated against Mycobacterium tuberculosis, M. avium and M. kansasii, eight bacterial strains including methicillin-resistant Staphylococcus aureus (MRSA) and for the inhibition of mycobacterial isocitrate lyase. Some compounds were further screened against drug-resistant M. tuberculosis and for their cytotoxicity. Minimum inhibitory concentrations (MICs) for all mycobacterial strains were within 0.5-32 μmol/L, with 4-chloro-2-[4-(trifluoromethyl)phenylcarbamoyl]phenyl 4-(trifluoromethyl)benzoate superiority. Gram-positive bacteria including MRSA were inhibited with MICs ³ 0.49 μmol/L, while Gram-negative ones were much less susceptible. Salicylanilide 4-(trifluoromethyl)benzoates showed significant antibacterial properties, for many strains being comparable to standard drugs (isoniazid, benzylpenicillin) with no cross-resistance. All esters showed mild inhibition of mycobacterial isocitrate lyase and four compounds were comparable to 3-nitropropionic acid without a direct correlation between in vitro MICs and enzyme inhibition.
- MeSH
- Anti-Bacterial Agents pharmacology MeSH
- Benzoates pharmacology MeSH
- Nitro Compounds pharmacology MeSH
- Isocitrate Lyase antagonists & inhibitors metabolism MeSH
- Methicillin-Resistant Staphylococcus aureus drug effects MeSH
- Microbial Sensitivity Tests MeSH
- Mycobacterium avium drug effects MeSH
- Mycobacterium kansasii drug effects MeSH
- Mycobacterium tuberculosis drug effects MeSH
- Propionates pharmacology MeSH
- Salicylanilides pharmacology MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- 3-nitropropionic acid MeSH Browser
- Anti-Bacterial Agents MeSH
- Benzoates MeSH
- Nitro Compounds MeSH
- Isocitrate Lyase MeSH
- Propionates MeSH
- salicylanilide MeSH Browser
- Salicylanilides MeSH